CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

You are here

Products

Products

back to search results

Glypican-3 [1G12]

Product information References Bioinformatics Documents
Product group: Primary
Monoclonal/ Polyclonal: Monoclonal
Clone: 1G12
Host: Mouse
Isotype: IgG1
Application: Flow cytometry (FC), Immunofluorescence (IF), Immunohistochemistry (IHC)
Application notes: 50-200
Conjugation Type: Unconjugated
Lightchain type: Kappa
Reactivity: Human
General notes: Localization: cytoplasm and membrane.
Buffer: Tris EDTA pH9.0
UNSPSC code: 12352203

Glypican-3 (GPC3) is a member of the glypican family of glycosyl phosphatidylinositol-anchored cell-surface heparan sulfate proteoglycans. GPC3 is a tissue and serum biomarker for the early detection of hepatocellular carcinoma. The anti-GPC3 antibody has been used to assess GPC3 expression in malignant and non-malignant liver tissue samples and for quantitative ELISA detection of GPC3 concentration in the serum. Capurro et al. have shown that GPC3 is expressed at the protein level by immunohistochemistry in most cases of primary liver cancer including small tumors, but is undetectable in normal liver and benign hepatic lesions. In addition, the authors found that GPC3 is significantly elevated in the serum of a large proportion of patients with Primary Liver Cancer. (Shipping Cost: €200.00)

Glypican-3 [1G12]

Glypican-3 (GPC3) is a member of the glypican family of glycosyl phosphatidylinositol-anchored cell-surface heparan sulfate proteoglycans. GPC3 is a tissue and serum biomarker for the early detection of hepatocellular carcinoma. The anti-GPC3 antibody has been used to assess GPC3 expression in malignant and non-malignant liver tissue samples and for quantitative ELISA detection of GPC3 concentration in the serum. Capurro et al. have shown that GPC3 is expressed at the protein level by immunohistochemistry in most cases of primary liver cancer including small tumors, but is undetectable in normal liver and benign hepatic lesions. In addition, the authors found that GPC3 is significantly elevated in the serum of a large proportion of patients with Primary Liver Cancer.